Literature DB >> 18466880

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Cameron S Carter1, Deanna M Barch, Robert W Buchanan, Ed Bullmore, John H Krystal, Jonathan Cohen, Mark Geyer, Michael Green, Keith H Nuechterlein, Trevor Robbins, Steven Silverstein, Edward E Smith, Milton Strauss, Til Wykes, Robert Heinssen.   

Abstract

This overview describes the generation and development of the ideas that led to the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. It also describes the organization, process, and products of the first meeting. The CNTRICS initiative involves a series of three conferences that will systematically address barriers to translating paradigms developed in the basic animal and human cognitive neuroscience fields for use in translational research aimed at developing novel treatments for cognitive impairments in schizophrenia. The articles in this special section report on the results of the first conference, which used a criterion-based consensus-building process to develop a set of cognitive constructs to be targeted for translation efforts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466880      PMCID: PMC2577821          DOI: 10.1016/j.biopsych.2008.03.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  Human pharmacological MRI.

Authors:  Garry Honey; Ed Bullmore
Journal:  Trends Pharmacol Sci       Date:  2004-07       Impact factor: 14.819

2.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

Review 3.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

Review 4.  Cognitive experimental approaches to investigating impaired cognition in schizophrenia: a paradigm shift.

Authors:  Angus W MacDonald; Cameron S Carter
Journal:  J Clin Exp Neuropsychol       Date:  2002-10       Impact factor: 2.475

Review 5.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

6.  Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative.

Authors:  Stephen R Marder; Wayne Fenton; Kenneth Youens
Journal:  Am J Psychiatry       Date:  2004-01       Impact factor: 18.112

  6 in total
  86 in total

1.  Brain mapping biomarkers of socio-emotional processing in schizophrenia.

Authors:  Stephan F Taylor; Angus W MacDonald
Journal:  Schizophr Bull       Date:  2011-09-30       Impact factor: 9.306

2.  Cognitive remediation therapy needs funding.

Authors:  Til Wykes
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 3.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

4.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

Review 5.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined.

Authors:  Gerhard Gründer; Hanns Hippius; Arvid Carlsson
Journal:  Nat Rev Drug Discov       Date:  2009-02-13       Impact factor: 84.694

Review 6.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

Review 7.  CNTRICS final task selection: control of attention.

Authors:  Keith H Nuechterlein; Steven J Luck; Cindy Lustig; Martin Sarter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

8.  Identifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophrenia.

Authors:  Matteo Cella; Anthony J Bishara; Evelina Medin; Sarah Swan; Clare Reeder; Til Wykes
Journal:  Schizophr Bull       Date:  2013-11-09       Impact factor: 9.306

9.  Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.

Authors:  Holly Moore; Mark A Geyer; Cameron S Carter; Deanna M Barch
Journal:  Neurosci Biobehav Rev       Date:  2013-09-30       Impact factor: 8.989

10.  Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?

Authors:  Joanne P Webster; Maya Kaushik; Greg C Bristow; Glenn A McConkey
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.